Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Don Hurst who wrote (182)	12/9/1997 9:33:00 AM
From: Harry D. Kramer	Read Replies (2) \| Respond to of 1510

Don, the Gruntal analyst raised his 12-month price target from $16 to $18. He thinks that, considering the huge potential markets for almost all of IMNR's clinical pipeline products, the company is undervalued and the development successes of the last quarters - represented by achieving most of its clinical milestones - were largely overlooked by Wall Street analysts. He also thinks that the likelihood of a major strategic alliance with a global pharmaceutical company has risen. This, of course, would also solve the upcoming cash problem. IMO, IMNR is still undervalued compared to its own potential and compared to similar development stage biotech companies. Remune alone has a fair value for this company of more than $30 per share, IF clinical development is successful. Of course, if it fails in Phase III, this stock will be down to $5 or less. However, based on all the clinical data we have seen so far, I think that probability of success - or let's better say approval - is way above 50%. Harry

To: Don Hurst who wrote (182)	12/12/1997 5:22:00 PM
From: Easy Mark	Respond to of 1510

It may be related to the Science article by Bruce Walker. This is what IRC said in a press release on Dec 4: "A recent publication in "Science" (November 21) reports on the importance of maintaining a virus-specific CD4 and T helper cell response in HIV infection. Specifically, Dr. Bruce Walker and his colleagues at Harvard showed there was a direct correlation between HIV-specific T cell proliferation and the successful control of virus replication in the absence of antiviral drug therapy in certain HIV-infected individuals. Dr. Walker and other researchers believe the new results provide some hope that these T helper cells could be boosted even in people who show little evidence of having them, possibly by combining powerful antiviral therapies with anti-HIV therapeutic vaccines. In our most recent published studies, we have shown that the administration of REMUNE to HIV-infected individuals elicits not only HIV-specific T cell proliferation, but also induces chemokines and gamma interferon along with a reduction in tumor necrosis factor, all of which are believed by scientists to have a favorable impact on disease progression." You can read a more detailed article by Stanley Moss (of IRC) at 207.226.163.175. If anyone can interpret the sci-fi jargon in either statement, please elucidate.